European Medicines Agency Restructures To Tackle New Challenges
Multiple Pressures Prompt ‘Future Proofing’ Exercise
A restructuring involving the setting up of four new task forces is aimed at improving how the European Medicines Agency responds to issues such as permanent staff reductions and challenges in regulatory science, digital business transformation, and clinical trial strategy.
You may also be interested in...
The recruitment process for the new executive director of the European Medicines Agency seems to be running to schedule.
EU regulators say that sponsors must complete their nitrosamine-related risk evaluations for all EU medicines containing chemically-synthesised active substances within the six-month timeframe.
The European Medicines Agency has taken possession of its new HQ in Amsterdam and has hired 77 new staff members to make up for the severe staff losses it has witnessed on account of Brexit.